D2.5 - Recommendations on the ethical principles, quality processes and stakeholder engagements for AI development
Deliverable 2.5 describes the ethical principles for GenoMed4All and similar AI driven projects and interventions for managing and risk assessing rare Haematological diseases. This description of principles draws from the European Commission Ethics Guidelines for Trustworthy Artificial Intelligence.
Abstract
Deliverable 2.5 summaries the proposed ethical principles for GenoMed4All and wider multi-omics and clinical data driven projects for rare diseases that involve the training and development of risk prediction and outcome measure algorithms that leverage artificial intelligence. D2.5 goes on to describe the approaches for stakeholder engagement (including clinical practitioners and sites, development teams, AI researchers and patient associations and the wider citizenry). This includes quality processes derived from the ethical principles where consideration of the ethical challenges around autonomy, bias and transparency in data use amongst others are pertinent.
Photo by Claudio Schwarz on Unsplash
